Wwtrnmt q f N d o g y , UUniveniry QPennryivmria &had QMediciue, fWadeiphia, Pennsylvania 19101 AB!3TRACT. A variety of peripheral neuropathies are M G , intravenous immune globulin believed to be imm~e-mediated. Acute Mammatory demyeliarting polyneuropathy or GuihbBarr6 syndrome (GBS) is the prototype of these neuropa&ks. GBS is characterized by acute progressive motor weakness of the extremities and of b a l k and facial musadatme. Deep tendon reflexes are reduced or abseat, and sensory symp GUILLAIN-BA& SYNDROME toms are mild. Respiratory failure and autonomic dysfunction may be seen. The cerehpioal fluid shows increased Clinical mpects. GBS is a distinct clinical entity characterized protein and no or very few cells. The nerve conduction by acute progressive motor weakness of the extremities and of velocity is slowed, and the pathology shows segmental bulbar and facial musculature. Deep tendon reflexes are reduced demyeli~mtion with mononuclear cell Miltration. Studies or absent and sensory symptoms are mild. from man and experimental animals suggest an immune
mme complexes have been found in patients with GBS.
Motor weakness usually develops rapidly. More than 90% of
The target antigen(s) for these antibodies are not well patients with GBS cease to progress within 4 wk into the disease.
understood, but neutral glycolipids cross-reactive with Recovery usually begins 2 to 4 wk after the cessation of progresForssman antigen and gangliosides are possible candidates. sion but may be delayed for months (1). Many patients are left The mainstay of therapy is the management of the para-with a residual deficit after 1 y (2). In another study, the median lyzed patient. Steroids are ineffective. Pksmapheresis, time of recovery to independent waking was 85 d, and for those especially early in the course of the disease, can shorten on a respirator it was 169 d (3). Autonomic dysfunction such as the duration of paralysis and intubation. Results from a cardiac arrhythmias, tachycardia, postural hypotension, and hymulticenter study in the Netherlands demonstrate the ef-pertension are seen and at times could be fatal. Conditions such fmcy of highdose immune globulin therapy in GBS. In as hexacarbon abuse, porphyria, diphtheria, lead poisoning, botthis review, Gllillrin-Barr6 syndrome as a putative im-ulism, toxic neuropathies, hysteria, tic paralysis, and poliomyemane-mediited neuropathy is d i i in detail. Chronic litis occasionally may be confused with GBS and need to be Mammatory demyeliarting polyneuropathy, neuropathks ruled out. associated with paraproteinemias, AIDS, and Lyme d i e Epidemiology. The incidence of GBS varies from 0.6 to 1.9/ ease are discussed briefly. Neuropathies with features of 100 000 per year (3). The disease is widely distributed throughout inflammation secondary to other infections and collagen the world. Children and adults of both sexes are affected. There vPscPlnr disorders are not the subject of this review. seems to be a bimodal distribution of patients, with the major there is
. . 
~t h e a c i a t i C m o t o r c o~o n , w h k h i s

* i n f i l t r r t i o n o f s n n a l l~i s n o t~b u t m r r p .
This form of EAN is clearly mediated through antibodies, and g a k k w x e w seems to be the target antigen (15,27,28 
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pathology simibr to GBS (30). A condition similar to GBS in patients with HIV infecton and bigh titer of a n h i to C.
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To date, no c o -v e evideace as to the inkdous etiology of GBS is availabk.
T h e l a n d m P r k w~o f P w b u r y e t d ( m P i s~b y~~~t e a n s e t ( I r w r a l l y 0 v e r m o n t h s ) of chro~ric pmgmsive, relapdng or chronic monophk course. Maximum dkidlity is usually reached after 6-12 mo, and peripberalnervedemyelinationcanbedcmonstratedbydectrophysiology and ~o l o g y (56, 57 
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with plasma exchange and i m m u n m v e tbapy (66). Dr. Frank: As was mentioned during the talks, several authors have shown that there are high levels of antibody to myelin in patients with GBS. What was not mentioned was that in studies done in our laboratory with Lee Koski and Moon Chen we also showed very high levels of membrane attack complex in most of those patients. We published one paper in the Journal of Clinical Investigation and two in Blood. We believe the way that M G works is that it prevents complement from binding to targets, and this mechanism was not even on your list.
Dr. Rostami: I apologize for that. I was attempting to expedite the presentation.
Dr. Frank: Also, a recent review article in the New England Journal of Medicine doesn't mention high levels of membrane attack complex either. I believe that is a real possibility and certainly worth further consideration.
Dr. Rostami: Absolutely. Dr. Roifman: You keep saying that plasmapheresis is effective in Guillain-Ban-4, but in fact the multicenter studies showed almost no effect of plasmapheresis. At best, the results were marginal, maybe a difference of a few days under a respirator.
That is an important issue because if plasmapheresis is effective, one may postulate that there may be a humoral factor involved. It may be implicated in the pathogenesis of the disease. Dr. Rostami: Multicenter studies have clearly shown that plasmapheresis is effective. In the American study, with 245 patients ( 123 in the conventionally treated group and 122 in the plasmapheresis arm), the percentage of patients who improved at least one grade at 1 mo was 59% in the plasmapheresis group versus 39% in the group treated conventionally. The French study also showed signi6cant improvement with plasmapheresis compared with the conventional group. That is an important issue as well, because if these patients are assessed 3 or 4 wk out, the milder cases are going to be very hard to assess.
Dr. Rostami: I have spoken to Dr. Franz van der Mechk, the principal investigator in the Dutch study. That study was done at nine centers with 150 consecutive patients, and they were randomized. I have seen the manuscript that has been submitted to the New England Journal of Medicine and have no doubt that the study was done correctly. They took patients in the first 2 wk of the disease and followed them for 6 mo, comparing M G and plasmapheresis. There was 53% improvement of strength, by one grade or more, with M G versus 34% with plasmapheresis. This study showed that IVIG was better than plasmapheresis, but there are a couple of criticisms of that study. First, more than 150 patients should be studied, at least 245 as in the North American study. Second, the rate of improvement with plasmapheresis was lower in this study than in the American study, which points to the question of whether the plasmapheresis was comparable to that of the American study.
Dr. Siami: I would like to elaborate a little bit about plasma exchange in GBS. The patient should not be able to walk more than 5 m, which indicates relatively severe disease, and the plasmapheresis should be started in the fvst week or 10 d to be useful.
